Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer .
Filed returns
40
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Pfizer | EU Affairs | Ireland’s priorities for the 2026 Presidency of the Council of the European Union, including issues related to life sciences competitiveness (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 19 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 9 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) | 9 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 7 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 7 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Access to an antiviral medication for the treatment of COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 6 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 15 | On lobbying.ie |
| May–Aug 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 14 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 9 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Ireland's medicine reimbursement system and Budget funding for new medicines (Matters involving public funds) | 9 | On lobbying.ie |
| May–Aug 2023 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 5 | On lobbying.ie |
| May–Aug 2023 | Pfizer | Health | Ireland's reimbursement system and funding for new medicines (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Economic Development and Industry | Pfizer recent 1.2 billion euro investment in Ireland operations creating 400-500 jobs (Public policy or programme) | 13 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Health | Ireland's pricing and reimbursement system and funding for new medicines (Public policy or programme) | 14 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Health | Pfizer anti-viral COVID-19 treatment and COVID-19 cases (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | EU Affairs | EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Budgetary matters | Budget 2023 (Public policy or programme) | 8 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Budgetary matters | Budget 2023 (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | COVID-19 vaccination programme (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | Pfizer COVID-19 anti-viral treatment (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2022 | Pfizer | Health | Update on Pfizer COVID 19 antiviral treatment and processes in ensuring availability of the treatment in Ireland (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | COVID-19 vaccination programme (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Health | Supply of Pfizer COVID-19 vaccine including Ireland volumes; expansion of manufacturing capacity to include Grange Castle site and Pfizer colleague vaccination programme (Public policy or programme) | 8 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Updates in relation to Pfizer COVID 19 vaccine including global production, Ireland volumes and company colleague vaccination programme (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2020 | Pfizer | Health | Discussions in relation to Pfizer/BioNtech progress in development of a vaccine for COVID 19 (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Economic Development and Industry | Welcomed committment to corporation tax policy and a supportive environment for FDI as outlined in the Programme for Government (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Highlighted discussions on extension of industry Supply Agreement and the importance of ensuring expenditure is efficently managed to ensure Irish patients can access innovative medicines; welcomed plans to progress the… (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Provided information about Pfizer's research into a COVID-19 vaccine, meeting sought with MoH/DoH. (Public policy or programme) | 29 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer launched 'MBC: A Call to Action' to highlight the unmet needs of metastatic breast cancer patients. MBC is an advanced form of breast cancer where early detection does not improve survival. Even if diagnosed with… (Public policy or programme) | 14 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Health | Ireland has now become one of the slowest countries in Europe to reimburse innovative medicines for patients. HTA assessment is prolonged and decisions after HTA are exceptionally slow with the majority of medicines… (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Economic Development and Industry | The Companies Act 2014 allowed for a Ministerial exemption from changing a company name to include the word 'unlimited' in the company name. This change would create significant administrative and cost burden for five… (Legislation) | 11 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 27 | 67.5% | |
| EU Affairs | 8 | 20.0% | |
| Economic Development and Industry | 3 | 7.5% | |
| Budgetary matters | 2 | 5.0% |